Scalable, single-use solutions for purification of viral vectors

 

I‌ndustrialization of cell and gene therapies requires robust, scalable manufacturing processes. Purification of viral vectors can be achieved using scalable, single-use technologies including direct-flow filtration (depth and sterile), membrane-based ion exchange chromatography, and tangential-flow filtration (TFF). Here we present a strategy for using these technologies from Pall for LV manufacturing platforms.

 

Speaker

Todd Sanderson

 

Sr. Manager R&D 

Pall, USA


Todd has been with Pall since 2006. He has over 20 years of research experience with expertise in mammalian cell culture, process development and analytical method development. He currently leads the Gene Therapy Upstream Cell Culture and Analytics Team in the Biotech Process R&D group. He holds a B.S. in Biochemistry and B.S. in Psychology from Michigan State University. When not at work, Todd enjoys gardening and spending time with his young children. 

Scalable, single-use solutions for purification of viral vectors

Learn about Transient transfection at large scale for clinical AAV9 vector manufacturing

Watch Rachel Legmann’s video presented during ICST 2020 Virtual event.

More Biotech Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
January 2022
Gene Therapy Downstream Manufacturing, Scale-up and Best Practices

Biotech | Pall Corporation webinar series

Meet the authors from the ‘Insights on Successful Gene Therapy Manufacturing and Commercialization’ ebook

Watch